Rate My Professor Graham Murray

Graham Murray is Clinical Professor of Psychiatry and Neuroscience in the Department of Psychiatry, School of Clinical Medicine, at the University of Cambridge. He serves as Honorary Consultant Psychiatrist in the Cambridge early intervention in psychosis service (CAMEO), part of Cambridgeshire and Peterborough NHS Foundation Trust, where he is one of the lead clinicians. Murray studied Physics and Philosophy at the University of Oxford and Medicine at King’s College London. He completed postgraduate psychiatric training in Cambridge and Suffolk, and research training at the University of Cambridge and the University of Oulu in Finland. He holds MD, PhD, and FRCPsych qualifications. Prior to his current professorship, awarded in 2023, he worked as a clinical lecturer, associate professor, and trainee at the University of Cambridge and CPFT.

Murray's research examines the causes, brain mechanisms, and treatments of mental disorders, primarily psychosis and depression. He utilizes epidemiology, neuroscience, computational psychiatry, genomics, electronic health records, and clinical trials to explore relationships between cognitive development across the lifespan and mental illness, as well as how etiological factors such as genetics lead to pathophysiological disruptions. His interests include applications of polygenic risk scores and clinical informatics risk prediction models. He jointly leads the early psychosis workstream of the NIHR Mental Health Translational Research Collaboration and the Office of Life Sciences/NIHR Mental Health Mission, and is chief investigator of the Early Psychosis Mission to enhance UK psychosis translational research infrastructure. Key publications include 'Predicting treatment resistance from first-episode psychosis using routinely collected clinical information' (2023, Nature Mental Health), 'Genetic insights into human cortical organization and development through genome-wide analyses of 2,347 neuroimaging phenotypes' (2023, Nature Genetics), 'Educational attainment, structural brain reserve and Alzheimer’s disease: a Mendelian randomization analysis' (2023, Brain), and 'Impaired reinforcement learning following chronic escitalopram as revealed by computational modelling and neuroimaging correlates' (2024, Neuroscience Applied).